Abiopharma

🔍 Bala Mohan (Executive)

Company: Mersana Therapeutics, Inc. (MRSN)

Report Date: 2025-10-25

Detailed Transactions and Holdings:

• Acquired 250 shares of Common Stock (Direct)
  Date: 2025-10-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,999.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Sold 77 shares of Common Stock at $9.9 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,922.00 | transaction_form_type: 4 | Footnotes: F3, F2, F2
• Sold 250 shares of Restricted Stock Unit (Derivative)
  Date: 2025-10-25 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F2, F5, F5, F2, F2

Footnotes:

• F1: Represents shares of common stock received upon vesting of the restricted stock units ("RSUs") awarded to the Reporting Person on October 25, 2021.
• F2: Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025.
• F3: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
• F4: Each RSU represents the contingent right to receive one share of common stock of the Issuer.
• F5: Fully vested as of October 25, 2025.